Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

최근(2003-2005) 우리나라 중부지역 소아에서 B형 간염 항체 보유율과 백신의 면역학적 기억에 대한 연구

A study of the current(2003-2005) prevalence of anti-HBs and immunologic memory of hepatitis B vaccine in children from the central area of Korea

  • 안영원 (단국대학교 의과대학 소아과학교실, 진단검사의학교실) ;
  • 정은희 (단국대학교 의과대학 소아과학교실, 진단검사의학교실) ;
  • 임인수 (단국대학교 의과대학 소아과학교실, 진단검사의학교실)
  • An, Young Won (Department of Pediatrics, College of Medicine, Dankook University) ;
  • Chung, Eun Hee (Department of Pediatrics, College of Medicine, Dankook University) ;
  • Rheem, Insoo (Department of Laboratory Medicine, College of Medicine, Dankook University)
  • 투고 : 2005.11.30
  • 심사 : 2006.02.24
  • 발행 : 2006.06.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : B형 간염 백신은 접종 후 시간이 경과하면서 항체가는 감소하나, 면역학적 기억은 약 10년 이상 유지되며, 항체가가 감소하더라도 임상적으로 의미있는 감염에 대한 예방효과가 있어 현재 정상 면역 기능을 가진 경우 3회 접종 후 예방 가능한 항체가 형성된 경우는 추가접종을 권장하고 있지 않다. 저자들은 최근 우리나라 중부지역 소아의 B형 간염 항체 보유율과 B형 간염 백신의 면역학적 기억에 대해 연구하고자 하였다. 방 법 : 2003년 3월부터 2005년 5월까지 단국대학교병원(병동, 외래)에서 간염 항원, 항체 검사(RIA, 혹은 EIA)를 받은 소아(6개월-18세)를 대상으로 하였고, 측정한 B형 간염 항체가가 10 IU/mL 이상인 경우를 양성으로 하였다. B형 간염 항체가가 음성인 소아 중 B형 간염 백신을 1회($Euvax^{(R)}$ 혹은 $Hepavaxgene^{(R)}$) 추가 접종한 후 1개월 후에 측정한 항체가가 10 mIU/mL 이상의 양전을 보인 경우를 면역기억반응이 있다고 정의하였다. HBsAg, anti-HBs를 검사받은 대상 중에서 $-20^{\circ}C$에 보관된 169명의 혈청에서 EIA로 IgG anti-HBc를 측정하였다. 결 과 : 총 3,448명이 RIA 또는 EIA로 HBsAg/anti-HBs 검사를 받았으며 그 중 3,277명(남아 1,923명, 여아 1,354명)을 연구 대상으로 하였다. 미숙아, 면역기능 저하자, 검사 전 수혈을 받았거나 면역글로불린을 투여 받은 소아를 제외한 3,277명 중에서 1,913명(58.4%)이 anti-HBs가 양성이었고, 그 중에서 남아는 1,115명(58.3%)이었다. HBsAg 양성은 29명(0.9%)였다. 나이에 따른 anti-HBs 양성률은 6-12개월까지는 78.6%(88/112명), 1-3세는 62.7%(455/726명), 4-6세는 51.9%(407/784명), 7-12세는 49.5%(441/890명), 13-15세는 63.4%(220/347명) 그리고 16-18세까지는 72.2%(302/418명)였다. 과거에 기본접종을 받았으나 HBsAg/anti-HBs 모두 음성을 보여 추가 접종을 받은 소아는 80명이었고, 1개월 뒤 측정한 간염 항체 검사 결과 양성률은 88.8%(71/80명), 무반응자는 9명이었다. IgG anti-HBc를 검사한 169명 중에서 5명(3.0%)이 양성을 보였고, 5명 모두 HBsAg이 음성이었다. 5명 중 anti-HBs가 음성인 소아가 4명으로 모두 1회 접종 후 항체 양전을 보였다. 결 론 : 우리나라 중부지역 소아의 B형 간염 항체 양성률이 나이가 들면서 감소를 보이고 있으나 1회 접종으로 10 IU/mL 이상으로 항체가 증가를 보여 이는 B형 간염 백신의 장기간의 면역학적 기억을 보여 주는 것으로 생각된다.

Purpose : This study was conducted to assess the current(2003-2005) prevalence of anti-HBs and immunologic memory for Hepatitis B vaccine in children from the central area of Korea. Methods : Subjects were chosen from children and adolescents who received tests for hepatitis B surface antigen(HBsAg) and anti-HBs at Dankook University Hospital from March 2003 to May 2005. Among these, antibodies to hepatitis B core antigen(IgG anti-HBc) were checked. A single booster vaccination was performed on children whose anti-HBs titers were under 10 mIU/mL. One month after booster vaccination we rechecked the anti-HBs titer. Results : A total of 3,277 subjects were tested for HBsAg/anti-HBs, and 1,913(58.4 percent) of them were positive for anti-HBs. Of these, 29 subjects(0.9 percent) were positive for HBsAg. Positive results for anti-HBs by age were 78.6 percent for 6-12 months of age, 62.7 percent for 1-3 years of age, 51.9 percent for 4-6 years of age, 49.5 percent for 7-12 years of age, 63.4 percent for 13-15 years of age and 72.2 percent for 16-18 years of age. The 80 subjects who were tested negative for HBsAg/anti-HBs received a single booster vaccine, 71 subjects were tested positive for antibodies. IgG anti-HBc titer was checked for 169 of the subjects, 5 subjects were positive. Conclusion : In our study, a significant anamnestic response was observed in 88.8 percent of children. This is believed to be a result of the relatively long immunologic memory effect of the hepatitis B vaccination in children from the central area of Korea.

키워드

과제정보

연구 과제 주관 기관 : 단국대학교

참고문헌

  1. Sim JG, Seo JK, Suh SJ. Prevalence and its changes of hepatitis B viral markers from 1988 to 1993 in Korean children. J Korean Pediatr Soc 1995;38:1535-8
  2. Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in medical staff of hemodialysis units. N Engl J Med 1982;307:1481-6 https://doi.org/10.1056/NEJM198212093072403
  3. Crosnier J, Jungers P, Courouce AM, Laplanche A, Benhamou E, Degos F, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units : II, Haemodialysis patients. Lancet 1981;1:797-800
  4. Szmuness W, Stevens CE, Oleszko WR, Goodman A. Passive- active immunisation against hepatitis B : immunogenicity studies in adult Americans. Lancet 1981;1:575-7
  5. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Demonstration of efficacy in a controlled clinical trial in a high risk population in the United State. N Engl J Med 1980;303:833-41 https://doi.org/10.1056/NEJM198010093031501
  6. Guideline of Immunization, 5th ed. The Korean Pediatric Society 2002:57
  7. Hepatitis B virus : a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee(ACIP). MMWR Recomm Rep 1991;40:1-25
  8. Seto D, West DJ, Ioli VA. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J 2002;21:793-5 https://doi.org/10.1097/00006454-200208000-00021
  9. Kim HW, Kim HS, Yang DO, Kim SJ. Immune responses of plasma derived HB vaccine for three years follow up. Korean J Med 1990;39:195-203
  10. Lee SJ, Han HK, Um MR, Choi KH, Lee MN, Yoo BH. Immune response to hepatitis B revaccination. Korean J Infect Dis 1996;28:59-66 https://doi.org/10.3109/00365549609027151
  11. Chang JY, Jeong SJ, Kim SK, Son BK, Hong YJ, Hong KS. Positive rate of HBsAg in school children in Incheon area. Korean J Pediatr Infect Dis 2003;10:153-8
  12. Kim CY. Immunoprophylaxis of hepatitis B. J Korean Med Assoc 1984;27:804-14
  13. Williams IT, Goldstein ST, Tufa J, TauilliiI S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003;22:157-63
  14. Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants : 10-year follow-up. J Infect Dis 1999;179:1319-25 https://doi.org/10.1086/314768
  15. Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004;23:650-5 https://doi.org/10.1097/01.inf.0000130952.96259.fd
  16. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Longterm immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003;187:134-8 https://doi.org/10.1086/345871
  17. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results. Arch Intern Med 1991;151:1634-6 https://doi.org/10.1001/archinte.151.8.1634
  18. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B : the role of vaccine immunogenicity in immune memory. Vaccine 2000;19:877-85 https://doi.org/10.1016/S0264-410X(00)00224-3
  19. Poland GA, Jacobson RM. Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351:2832-8 https://doi.org/10.1056/NEJMcp041507
  20. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-result of a 10-year study. J Infect Dis 1997;175:674-7 https://doi.org/10.1093/infdis/175.3.674
  21. Ding L, Zhang M, Wang Y, Zhou S, Kong W, Smego RA Jr. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993;17:475-9 https://doi.org/10.1093/clinids/17.3.475
  22. Duval B, Gilca V, Boulianne N, De Wals P, Masse R, Trudeau G, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005;24:213-8 https://doi.org/10.1097/01.inf.0000154329.00361.39
  23. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen : implications for policy on booster vaccination. Vaccine 1996;14:1019-27 https://doi.org/10.1016/0264-410X(96)00062-X
  24. European consensus group on hepatitis B immunity. Are booster immunization needed for lifelong hepatitis B immunity? Lancet 2000;355:561-5 https://doi.org/10.1016/S0140-6736(99)07239-6
  25. Waston BM, Di Prinzio S, West D. Persistence of hepatitis B antibody and anamnestic response to a booster dose in healthy adolescents and adults. Abstract 32, the 32nd National Immunization Conference : 1998 July 21-24; Atlanta, GA
  26. Lai CL, Lau JY, Yeoh EK, Chang WK, Lin HJ. Significance of isolated anti-HBc seropositivity by ELISA : implications and the role of radioimmunoassay. J Med Virol 1992;36:180-3 https://doi.org/10.1002/jmv.1890360306
  27. Aoki SK, Finegold D, Kuramoto IK, Douville C, Richards C, Randell R, et al. Significance of antibody to hepatitis B core antigen in blood donors as determined by their serologic response to hepatitis B vaccine. Transfusion 1993;33: 362-7 https://doi.org/10.1046/j.1537-2995.1993.33593255593.x
  28. McIntyre A, Nimmo GR, Wood GM, Tinniswood RD, Kerlin P. Isolated hepatitis B core antibody - can response to hepatitis B vaccine help elucidate the cause- Aust N Z J Med 1992;22:19-22 https://doi.org/10.1111/j.1445-5994.1992.tb01703.x
  29. Williams JL, Christensen CJ, McMahon BJ, Bulkow LR, Cagle HH, Mayers JS, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 2001;19:4081-5 https://doi.org/10.1016/S0264-410X(01)00112-8
  30. Lai CL, Wong BC, Yeoh EK, Lim WL, Chang WK, Lin HJ. Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasmaderived vaccine in children : immunogenicity and anamnestic responses. Hepatology 1993;18:763-7 https://doi.org/10.1002/hep.1840180403
  31. Epidemiology and prevention of vaccine-preventable diseases, 8th ed. Published by National Immunization Program, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. chapter 15. Hepatitis B. 2005:207
  32. West DJ, Watson B, Lichtman J, Hesley TM, Hedberg K. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Pediatr Infect Dis J 1994;13:745-7 https://doi.org/10.1097/00006454-199408000-00015